Abstract
51342 Four-weekly dosing intervals with subcutaneous spesolimab appear to be required for optimal prevention of generalized pustular psoriasis flares: Data from the Effisayil 2 and Effisayil ON trials
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have